Physcion increases the sensitivity of hepatocellular carcinoma to sorafenib through miRNA-370/PIM1 axis-regulated glycolysis

Figure 2 Physcion promotes sorafenib sensitivity of sorafenib-resistant hepatocellular carcinoma cells. SF-resistant Huh7-SR and HepG2-SR cells were treated with physcion and/or SF. A: Cell proliferation was measured by colony formation; B: Cell viability was checked by cell counting kit 8 assay; C: TUNEL assay was conducted to measure cell apoptosis; D and E: Huh7-SR cells (D) and HepG2-SR cells (E) were labeled with Annexin V and PI and detected by flow cytometry to determine cell apoptosis; F and G: The protein levels of Bcl-2, Bax, cleaved caspase-3 and cleaved PARP in (F) Huh7-SR cells and (G) HepG2-SR cells were analyzed by western blotting. ^aP < 0.05 versus control (Cont) group; ^bP < 0.05 versus Cont + SF group. Cont: Control; SF: Sorafenib; phy: Physcion; NS: No significant.